INTRODUCTION
The treatment of rheumatoid arthritis (RA) includes biologic disease-modifying antirheumatic drugs (bDMARD) that may slow down and control disease progression. Because RA is a chronic disease process, it is essential that patients be periodically assessed for evidence of disease activity or progression [1] .
Recurring flares or progressive joint damage may require physicians to consider changes to the patient's bDMARD regimen. Results from randomized controlled trials indicate that about one-third of RA patients initially treated with anti-tumor necrosis factor a (anti-TNF) agents do not respond, show a suboptimal response, lose response, or develop adverse events [1] . RA patients whose anti-TNF agent as their first bDMARD has failed or who must stop an anti-TNF for some other reason may then switch to another bDMARD, either another anti-TNF agent or a bDMARD with another mechanism of action (MOA).
However, evidence has been mixed [2, 3] The RAPID3 score ranges from 0 to 30, with higher scores indicating more severe disease [4, 5] . RAPID3 provides a feasible approach to monitoring disease activity in the real-world setting. It was used to measure response in this study because it correlates well with other measure of disease activity [4, 5] that may not be routinely available from patient charts.
Unless they had discontinued the bDMARD before the 6-month time point, patients were required to have RAPID3 scores at baseline and at 6 months on treatment for their second or third bDMARD to be eligible for analysis. For the baseline measure, patients had to have a RAPID3 score on the date the biologic was started or up to 6 weeks before the bDMARD start date. Follow-up was defined as 6 months after bDMARD start date, with a window of plus or minus 8 weeks (i.e., 16-32 weeks after the start date).
The 6-month follow-up score was compared with the baseline score to determine RAPID3 response. Good response was defined as a decrease in RAPID3 score of greater than 3.6 points and a follow-up score less than 6. Poor response was defined as a decrease of less than 1.8 points or a decrease between 1.8 and 3.6 points and a follow-up score greater than 12 [6] . In addition, if a patient discontinued therapy before 6 months, the patient was defined as having a poor response. Patients classified as neither good nor poor responders were considered to have had a moderate response.
RAPID3 change scores were calculated by subtracting the baseline score from the 6-month follow-up score. If a patient discontinued therapy before 6 months, the RAPID3 score at the time of discontinuation (plus or minus 4 weeks) was used as the follow-up score.
Patients who discontinued but did not have a RAPID3 score available were excluded from this analysis.
The percentages of patients with good RAPID3 response and good or moderate response (i.e., not poor response) were compared between treatments (anti-TNF vs.
other MOA) using the Chi square test, and mean change in RAPID3 was compared between treatments using the t test. These analyses were stratified by the order of the subsequent bDMARD (i.e., second or third).
Mixed multivariate models were used to account for correlation of multiple observations per patient because data from both second and third biologics were included in the models, if eligible. These models evaluated the effect of treatment (anti-TNF vs.
other MOA) on the 6-month RAPID3 outcomes adjusted for potential confounders: age, sex, race/ethnicity, cyclic citrullinated peptide or rheumatoid factor positivity, and baseline
RAPID3.
Previous research has suggested that patients who have discontinued one anti-TNF because of lack of efficacy are more likely to discontinue a subsequent anti-TNF agent for the same reason.
To assess this occurrence in our study, we included an interaction term for current bDMARD (anti-TNF vs. other MOA) with reason for discontinuation of the previous anti-TNF (lack of efficacy vs. other reason).
Lack of efficacy included discontinuation of the anti-TNF because of either primary nonresponse or secondary non-response (or loss of efficacy after initial response). This subanalysis included all second bDMARD treatments in our data set; third bDMARD treatments were included only if an anti-TNF was the second bDMARD.
All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
One hundred seventy-six patient charts were abstracted. By study design, all patients received a second bDMARD after discontinuing their first anti-TNF. In addition, 98 patients received a third bDMARD. Treatment sequences are shown in Table 1 . Most patients received another anti-TNF after discontinuing the first anti-TNF (n = 122; 69.3%). Seventy-nine patients discontinued a second anti-TNF, of these 29 (36.7%) received a third anti-TNF, and 50 received a bDMARD with another MOA.
The most common reasons for discontinuation of the first anti-TNF were efficacy related (69% discontinued because of lack of initial efficacy or failure to maintain a response). Lack of initial efficacy (primary nonresponse) was a more common reason for discontinuation as treatment order progressed:
23% of first anti-TNF patients, 40% of second anti-TNF patients, and 48% of third anti-TNF patients discontinued for this reason. In addition, safety/tolerance was reported as a reason for discontinuation more often for anti-TNF as the subsequent biologic (21% for second and 19% for third) than for subsequent bDMARD with other MOA (14% for second and 5% for third).
After excluding treatments when RAPID3 scores were not available for analysis, 215 subsequent bDMARD treatments from 160 patient charts in the analysis of RAPID3 response remained. Of these, 144 were the second bDMARD treatment (101 anti-TNF, 43
other MOA), and 71 were the third bDMARD treatment (29 anti-TNF, 42 other MOA).
Among the 160 patients available for RAPID3 analysis, 121 (75.6%) were female, 139 (86.9%) were white non-Hispanic, and 87 (54.4%) were cyclic citrullinated peptide or rheumatoid factor positive. Mean age at RA diagnosis was 50.0 ± 13.6 years, age at second bDMARD initiation was 56.7 ± 13.0 years, and mean number of years from diagnosis to time of chart review was 9.9 ± 7.2. These characteristics were similar for anti-TNF and other MOA treatments ( Table 2) . As shown in Table 2 , the RAPID3 score at baseline was similar for patients receiving anti-TNF and other MOA treatments as second P\0.01) than patients receiving an anti-TNF. These patterns were similar when analyzing the third bDMARD, but none were statistically significant.
One of the criteria for poor response was discontinuation of treatment before 6 months.
Patients receiving an anti-TNF as the second bDMARD were more likely to meet this criterion than those receiving another MOA as the second bDMARD (28.7 vs. 11.6%, respectively; P = 0.03); though similar trends were observed, this finding was not statistically significant for the third bDMARD (41.4 vs. 21.4%; P = 0.07).
After data from subsequent treatments (second and/or third biologic) were included and adjusted for covariates, results of the multivariate mixed models were derived and are shown in Table 4 
DISCUSSION
In this exploratory analysis of RA patients who discontinued an anti-TNF agent as their first bDMARD, patients receiving agents with other MOA rather than another anti-TNF as their second or third bDMARD were more than twice as likely to achieve a good or a good or moderate RAPID3 response at 6 months after adjusting for patient demographics, seropositivity, and baseline RAPID3 score. In addition, they showed greater improvement Anti-TNF Anti-tumor necrosis factor a, CI Confidence interval, MOA Mechanism of action, OR Odds ratio, RAPID3 Routine Assessment of Patient Index Data 3 a Results adjusted for age, sex, race/ethnicity, cyclic citrullinated peptide or rheumatoid factor positive, and baseline RAPID3
(decrease) in RAPID3 score at 6 months.
Although similar patterns were observed with the third bDMARD, statistical significance was not observed. However, patient numbers were smaller and power for analyzing the third bDMARD was lower. Because of these factors, data for the second and third bDMARDs were combined in the multivariate analysis. Despite having failed an anti-TNF as their first bDMARD, most patients went on to receive another anti-TNF agent as their second bDMARD, and several received another as their third. In a 2006 US survey, 94% of the rheumatologists who responded reported that they switch patients to another anti-TNF agent if the first anti-TNF agent is ineffective or not well tolerated [7] . In the current study, this percentage was 69%, perhaps because more treatment options were available than at the time of the 2006 survey. Even in the current study, however, this treatment pattern represents a large proportion of patients. Although some studies suggest that a second anti-TNF is effective in patients after the first anti-TNF agent has failed [8] , others suggest that response rates for the subsequent anti-TNF agents are progressively lower than for patients using an anti-TNF as their first bDMARD [9] [10] [11] [12] .
Given the choice of therapeutic options with other MOAs available to patients, the relevant clinical question is whether patients should receive therapy with a different MOA after an anti-TNF agent has failed. Our study is consistent with other studies that have shown that switching to a different MOA might be the more effective strategy.
In several studies of RA patients whose first anti-TNF treatment failed, patients receiving rituximab had better improvement in Disease Activity Score at 28 joints (DAS28) than patients treated with a second anti-TNF [13] [14] [15] [16] . A recent Bayesian network meta-analysis [17] of RA patients whose first line anti-TNF failed found that patients receiving bDMARDs with other MOA did better than patients receiving a second anti-TNF agent, as measured by American College of Rheumatology 20 (ACR20) response criteria. Compared with second anti-TNF agents, tocilizumab had an OR of 3.52, rituximab had an OR of 1.87, and abatacept had an OR of 1.64 [17] .
A Swiss study found that the benefit of rituximab varied with the reason for switching from a previous TNF inhibitor [15] . Rituximab patients showed greater decrease in DAS28 at 6 months than patients treated with another anti-TNF if the switch occurred because of lack of efficacy. When the switch occurred for another reason, however, the decrease in DAS28 was similar. In the current analysis, we did not find a significant interaction between reason for switching from the previous anti-TNF and response to a biologic with another MOA versus another anti-TNF.
Interpretation [18, 19] . We also did not assess the impact of choice of concomitant nonbDMARD on study outcomes. Further research assessing individual treatments in the other MOA group against anti-TNF agents while adjusting for the concomitant non-bDMARD is warranted.
One strength of this analysis is that patients who discontinued treatment were included in the analysis using conservative assumptions. Patients who discontinued bDMARD treatment before 6 months were included in the analysis as poor responders, and their RAPID3 scores at the time of discontinuation, if available, were included for change score calculation. Thus, results were not biased by including only patients who did well on treatment. Our study evaluated the use of an anti-TNF agent compared with another MOA as the second bDMARD and separately as the third bDMARD, which has not been done before this study. In both assessments, the trends were consistent and suggested that patients using other MOAs had better outcomes.
CONCLUSION
In conclusion, this study was consistent with previous research in finding that among patients who discontinued anti-TNF agents as their first bDMARD, response rates (as measured by RAPID3 in this study) are better for patients receiving agents with a different MOA rather than another anti-TNF agent. Physicians should consider using a bDMARD with a different MOA as the next bDMARD for RA patients whose treatment with an anti-TNF agent failed.
Further research should focus on determining which specific bDMARD with a non-TNF MOA would provide the most benefit to RA patients.
Conflict of interest.
Martin Bergman is a consultant for AbbVie, Amgen, Genentech (Roche), Janssen, and Pfizer; he is a member of the speakers' bureau for AbbVie, BMS, Pfizer, and UCB; and he owns stock in Pfizer. Eric Elkin is an employee of ICON Clinical Research, which was paid by Genentech, Inc., to conduct the study and to provide biostatistical services. ICON is also paid by other pharmaceutical, biotechnology, and medical device companies to provide these services.
Sarika Ogale is an employee of Genentech, Inc. Tripthi Kamath is an employee of Genentech, Inc. Max Hamburger is a member of the speakers' bureau for AbbVie, BMS, Pfizer, and UCB. 
